<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341379</url>
  </required_header>
  <id_info>
    <org_study_id>10-007806</org_study_id>
    <secondary_id>R01HD058567</secondary_id>
    <nct_id>NCT01341379</nct_id>
  </id_info>
  <brief_title>Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate</brief_title>
  <official_title>Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors
      of metabolism. The investigators propose to determine if short-term (3 day) treatment with
      N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients.
      The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators
      would consider more extensive long-term studies of the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To determine whether brief (3 day) treatment with N-carbamylglutamate can improve
           ureagenesis in adult healthy controls and patients with the following inborn errors of
           metabolism: N-acetylglutamate synthetase deficiency, propionic acidemia, methylmalonic
           acidemia, carbamylphosphate synthase deficiency, ornithine transcarbamylase deficiency
           and the syndrome of hyperammonemia, hypoglycemia and hyperinsulinemia (HHH Syndrome).

        -  To determine if such treatment improves other indicators of abnormal nitrogen metabolism
           such as elevated blood levels of glutamine, glycine and alanine.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of ureagenesis</measure>
    <time_frame>3 days</time_frame>
    <description>Goal is to determine whether a 3 day trial of N-carbamylglutamate increases ureagenesis in patients with urea cycle defects and other inborn errors of metabolism.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Urea Cycle Disorders, Inborn</condition>
  <condition>Inborn Errors of Metabolism</condition>
  <condition>Propionic Acidemia</condition>
  <condition>Methylmalonic Acidemia</condition>
  <condition>Carbamyl Phosphate Synthetase Deficiency</condition>
  <arm_group>
    <arm_group_label>N-carbamylglutamate (Carbaglu)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-carbamylglutamate</intervention_name>
    <description>N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses</description>
    <arm_group_label>N-carbamylglutamate (Carbaglu)</arm_group_label>
    <other_name>Carbaglu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range: males or females, ages 3 years - 70 years

          -  Condition(s): N-acetylglutamate synthetase deficiency, propionic acidemia,
             methylmalonic acidemia, carbamylphosphate synthase deficiency, ornithine
             transcarbamylase deficiency and the syndrome of hyperammonemia, hypoglycemia and
             hyperinsulinemia.

          -  In addition, healthy volunteers will be studied (ages 18 years - 50 years).

        Exclusion Criteria:

          -  Acutely ill on day of study (fever, evidence of hyperammonemia - ataxia, worsening
             obtundation, focal neurologic signs, seizures, increased intracranial pressure,
             vomiting, signs of acute respiratory or enteric illness, headache, confusion,
             disorientation, acute personality change).

          -  Girls 11 years of age must have a negative urine/serum pregnancy test within 1 week
             prior to testing unless having a menstrual period during week of test

          -  Lactating females

          -  Hyperammonemia probably refractory to N-carbamylglutamate: other urea cycle disorders
             (UCD), lysinuric protein intolerance, mitochondrial disorders, congenital lactic
             acidemia, fatty acid oxidation defects or primary liver disease.

          -  Amount of blood necessary for study exceeds safe limits.

          -  Any investigational drug use within 30 days prior to enrollment.

          -  Parents/guardians or subjects who, in the opinion of the PI, may be non-compliant with
             study schedules or procedures.

          -  Subjects who do not meet all the enrollment criteria may not be enrolled. Any
             violations of these criteria will be reported in accordance with Institutional Review
             Board (IRB) Policies and Procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Yudkoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/ucdc/</url>
    <description>Urea Cycle Research Consortium</description>
  </link>
  <results_reference>
    <citation>Ah Mew N, McCarter R, Daikhin Y, Nissim I, Yudkoff M, Tuchman M. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics. 2010 Jul;126(1):e208-14. doi: 10.1542/peds.2010-0008. Epub 2010 Jun 21.</citation>
    <PMID>20566609</PMID>
  </results_reference>
  <results_reference>
    <citation>Yudkoff M, Ah Mew N, Daikhin Y, Horyn O, Nissim I, Nissim I, Payan I, Tuchman M. Measuring in vivo ureagenesis with stable isotopes. Mol Genet Metab. 2010;100 Suppl 1:S37-41. doi: 10.1016/j.ymgme.2010.02.017. Epub 2010 Feb 26.</citation>
    <PMID>20338795</PMID>
  </results_reference>
  <results_reference>
    <citation>Ah Mew N, Payan I, Daikhin Y, Nissim I, Nissim I, Tuchman M, Yudkoff M. Effects of a single dose of N-carbamylglutamate on the rate of ureagenesis. Mol Genet Metab. 2009 Dec;98(4):325-30. doi: 10.1016/j.ymgme.2009.07.010. Epub 2009 Jul 14. Erratum in: Mol Genet Metab. 2010 Apr;99(4):440.</citation>
    <PMID>19660971</PMID>
  </results_reference>
  <results_reference>
    <citation>Tuchman M, Caldovic L, Daikhin Y, Horyn O, Nissim I, Nissim I, Korson M, Burton B, Yudkoff M. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res. 2008 Aug;64(2):213-7. doi: 10.1203/PDR.0b013e318179454b.</citation>
    <PMID>18414145</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2011</study_first_submitted>
  <study_first_submitted_qc>April 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Marc Yudkoff</investigator_full_name>
    <investigator_title>Division Chief</investigator_title>
  </responsible_party>
  <keyword>Ureagenesis</keyword>
  <keyword>Urea cycle</keyword>
  <keyword>Inborn errors of metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Propionic Acidemia</mesh_term>
    <mesh_term>Carbamoyl-Phosphate Synthase I Deficiency Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

